{
    "clinical_study": {
        "@rank": "50164", 
        "acronym": "LID in PD", 
        "arm_group": [
            {
                "arm_group_label": "AVP-923-45", 
                "arm_group_type": "Experimental", 
                "description": "AVP-923-45 twice daily for 14 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo twice a day for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg\n      dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of\n      levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD)."
        }, 
        "brief_title": "Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dyskinesia", 
            "Parkinson's Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyskinesias", 
                "Parkinson Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Proof-of-concept phase 2a, double-blind, randomized, placebo-controlled, crossover study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females 30 to 80 years of age, inclusive.\n\n          -  Diagnosis of idiopathic PD meeting the United Kingdom Parkinson's disease Society\n             Brain Bank criteria.\n\n          -  Levodopa-induced dyskinesia present greater than 25% of the day as per MDS-UPDRS.\n\n          -  Dyskinesia of at least moderate severity as per MDS-UPDRS\n\n          -  Amantadine and Monoamine Oxidase (MAO) inhibitors must be discontinued at least three\n             weeks prior to randomization.\n\n          -  Subjects currently receiving anti-parkinsonian medications, including all Levodopa\n             preparations are eligible provided they have been on a stable dose of these\n             medications for at least 1 month prior to randomization.\n\n          -  Concomitant use of antidepressants such as selective serotonin reuptake inhibitors\n             are allowed, provided the dose has been stable for at least 1 month prior to\n             randomization.\n\n        Exclusion Criteria:\n\n          -  Subject had a prior surgery for PD except Deep Brain Stimulation (Deep Brain\n             Stimulation must not have been performed within one year of screening)\n\n          -  Hoehn and Yahr score of 5 when \"off\".\n\n          -  Subject with Cognitive impairment and/or history of psychiatric manifestations or\n             active hallucinations.\n\n          -  Subjects with any history of complete heart block, QTc prolongation, or torsades de\n             pointes.\n\n          -  Subjects with any family history of congenital QT interval prolongation syndrome.\n\n          -  Subjects with history of postural syncope, or any history of unexplained syncope\n             within the last 12 months.\n\n          -  Subjects with a history of substance and/or alcohol abuse within the past 2 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767129", 
            "org_study_id": "12-AVR-133"
        }, 
        "intervention": [
            {
                "arm_group_label": "AVP-923-45", 
                "description": "One capsule twice daily for 14 days", 
                "intervention_name": "AVP-923-45", 
                "intervention_type": "Drug", 
                "other_name": "dextromethorphan/quinidine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "One capsule twice daily for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dextromethorphan", 
                "Levodopa", 
                "Quinidine", 
                "Quinidine gluconate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "levodopa", 
            "dyskinesia", 
            "parkinson's disease", 
            "AVP-923", 
            "dextromethorphan", 
            "quinidine"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2S8"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.", 
        "overall_contact": {
            "email": "spatel@avanir.com", 
            "last_name": "Sonal Patel", 
            "phone": "949-389-6791"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Unified Dyskinesia Rating Scale (UDysRS), part 3", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767129"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "UDysRS, part 4", 
                "safety_issue": "No", 
                "time_frame": "2 Weeks"
            }, 
            {
                "measure": "Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks"
            }, 
            {
                "measure": "Bradykinesia", 
                "safety_issue": "No", 
                "time_frame": "2 Weeks"
            }, 
            {
                "measure": "MDS-UPDRS part I, II, and IV", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks"
            }, 
            {
                "measure": "UDysRS part 1 and 2", 
                "safety_issue": "No", 
                "time_frame": "2 Weeks"
            }, 
            {
                "measure": "PD Motor Diary", 
                "safety_issue": "No", 
                "time_frame": "2 Weeks"
            }
        ], 
        "source": "Avanir Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Avanir Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}